# Moderna Q3 Profit Rises 29% To $1.3 Billion

> Moderna reports $162 million profit and raises 2026 revenue outlook after strong international vaccine sales.
- Title: Moderna Q3 Profit Rises 29% To $1.3 Billion · Pulse 2.0
- Summary: Moderna reports $162 million profit and raises 2026 revenue outlook after strong international vaccine sales.
- Keywords: moderna, q3 revenue, profit, vaccine sales, international markets, revenue outlook, oncology, rare disease, mflusiva, intismeran, propionic acidemia, cash position
- Source: Pulse 2.0 — https://pulse2.com/moderna-q3-revenue-rises-29-to-1-3-billion-as-company-reports-162-million-profit-and-raises-2026-outlook
- Author: Amit Chowdhry
- Published: 2026-11-09T19:26:11+00:00
- Read time: 1 min
- Topics: moderna, q3 revenue, profit, vaccine sales, international markets, revenue outlook, oncology, rare disease, mflusiva, intismeran, propionic acidemia, cash position
## Moderna Q3 Results
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and returned to quarterly profitability with net income of $162 million.
## Revenue Breakdown
U.S. revenue totaled $780 million, while international markets contributed $533 million.
## Profit Improvement
Net income improved by $362 million year-over-year, compared with a net loss of $200 million during the prior-year quarter.
## Earnings Per Share
Diluted earnings per share reached $0.38, compared with a loss of $0.51 per share a year earlier.
## Operating Performance
Moderna reported operating income of $130 million, reversing an operating loss of $260 million in the third quarter of 2025.
## Cost Reductions
Research and development expenses declined 27% to $583 million, compared with $801 million a year earlier.
## Full-Year Outlook
Moderna raised its full-year revenue growth outlook to 15%, 25%, exceeding its previous forecast of up to 10% growth.
## International Expansion
Moderna signed a five-year agreement with a local manufacturer in Mexico involving COVID-19 vaccines, supporting its international expansion.
## Oncology Progress
Moderna and Merck presented positive Phase 3 results for intismeran in melanoma, reducing recurrence risk by 42%.
## Rare Disease Pipeline
Moderna’s mRNA-3927 treatment for propionic acidemia reached target enrollment with pivotal results expected in 2026.
## Cash Position
Moderna’s cash position strengthened to approximately $8 billion as of September 30, 2.026.
## Future Focus
Moderna enters final quarter of 2026 focused on commercial execution, pipeline development, and financial discipline.
## Key takeaway

Moderna achieved $1.3 billion Q3 revenue with $162 million profit, raising full-year growth forecast to 15%-25%.